Multimodality Approach to Management of Stage III Non-Small Cell Lung Cancer

Surgical Oncology Clinics of North America

Volumn 22, Issue 2, 2013, Pages 319-328

  Scarpaci, Anthony ^a   Mitra, Priya ^a   Jarrar, Doraid ^a   Masters, Gregory A ^b  

^a EINSTEIN MEDICAL CENTER   (United States)

^b HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

Multimodality approach; Neoadjuvant treatment; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG TARGETING; EGFR GENE; EML4 ALK GENE; ENDOBRONCHIAL ULTRASONOGRAPHY; FEBRILE NEUTROPENIA; FOLLOW UP; GENE; GENE MUTATION; GENE REARRANGEMENT; GENETIC MARKER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MEDIASTINOSCOPY; OVERALL SURVIVAL; REVIEW; SURVIVAL TIME; THORACOTOMY;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 84875521324     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2012.12.014     Document Type: Review

References (16)

1. Jernal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Fry W., Menck H., Winchester D. The National Cancer Data Base report on lung cancer. Cancer 1996, 77:1947-1955.
3. Albain K.S., Swann R.S., Rusch V.R., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005, 23:16S.
4. Belani C.P., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.
5. Perez C.A., Stanley K., Rubin P., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung: preliminary report by Radiation Therapy Oncology Group. Cancer 1980, 45:2744-2753.
6. Rosell R., Gómez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994, 220(3):153-158.
7. Rosell R., Gómez-Codina J., Camps C., et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999, 26(1):7-14.
8. Roth J.A., Fossella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994, 86(9):673-680.
9. Pisters K.M., Vallières E., Crowley J.J., et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010, 28(11):1843-1849.
10. Douillard J.Y., Rossell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 2006, 7:719-727.
11. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
12. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995, 13:1880-1892.
13. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
14. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
15. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009, 373:1525-1531.
16. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.